According to World Health Organization (WHO) Fact Sheet, depression is a “common illness worldwide, with more than 300 million 51 people affected. Panic attack treatment is the type of treatment for Selective serotonin reuptake inhibitors (SSRIs). Panic attack and anxiety attack are the two different attacks. Panic attacks are unprovoked and unpredictable. Yoga and deep breathing may help to reduce incidences of panic attack. There are various symptoms of panic attack such as sweating, trembling, shortness of breath, a choking sensation, chest pain, nausea, dizziness, fear of losing your mind, fear of dying, feeling hot or cold and numbness or tingling. These type of attacks are happens anywhere and anytime.This growth is primarily driven by Rising Prevalence of Depression and Panic Attacks due to Unhealthier Lifestyles and Increasing Awareness about Panic Attack Treatments.
Globally, a noticeable market trend is evident Emergence of Comparatively more Effective and Efficient Panic Attack Treatments
. Major Players, such as Pfizer Inc. (United States), GlaxoSmithKline (United Kingdom), Merck & Co. Inc. (United States), Sanofi-Aventis (France), AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), F-Hoffmann-La Roche (Switzerland) and Shionogi and Company (Japan) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Key Developments in the Market:
On 19th December 2018, GlaxoSmithKline Plc. (GSK) has confirmed an agreement with Pfizer Inc. to form joint venture which will combine their consumer health businesses with combined trades of around 12.7 USD billion. Pfizer will have an equity interest of 32% in the Joint Venture. On the other hand, GSK will have a majority controlling equity interest of 68%.
In 2004, the United States’ Food and Drug Administration (FDA) has mandated all the depression drug manufacturers to add a boxed warning to the labelling of all antidepressant medications. This labelling should warn about the rising risks of suicidal thinking or suicidal behaviour in children and adolescents taking antidepressants during initial treatment and with dose increases. Moreover, in 2007, FDA requested that the warning be extended to include young adults through age 24.
- Rising Prevalence of Depression and Panic Attacks due to Unhealthier Lifestyles
- Increasing Awareness about Panic Attack Treatments
- Emergence of Comparatively more Effective and Efficient Panic Attack Treatments
- Growing Adoption of SSRI Antidepressants
- Availability of Favorable Reimbursement Policies for Medications and Therapies
- Limited Patent Validity Timeline for Branded Depression Drugs
- Adverse Side Effects from Panic Attack Drugs
Surging Technological Advancements in Mental Health Drug Development and Robust Investments in Research and Development for ongoing Drug Discovery
Lack of Healthcare Infrastructure in Underdeveloped Countries and Complexities in International Drug Trades
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase